Literature DB >> 16469744

Myocyte enhancer factors 2A and 2C induce dilated cardiomyopathy in transgenic mice.

Jian Xu1, Nanling L Gong, Ilona Bodi, Bruce J Aronow, Peter H Backx, Jeffery D Molkentin.   

Abstract

Cardiac hypertrophy and dilation are mediated by neuroendocrine factors and/or mitogens as well as through internal stretch- and stress-sensitive signaling pathways, which in turn transduce alterations in cardiac gene expression through specific signaling pathways. The transcription factor family known as myocyte enhancer factor 2 (MEF2) has been implicated as a signal-responsive mediator of the cardiac transcriptional program. For example, known hypertrophic signaling pathways that utilize calcineurin, calmodulin-dependent protein kinase, and MAPKs can each affect MEF2 activity. Here we demonstrate that MEF2 transcription factors induced dilated cardiomyopathy and lengthening of myocytes. Specifically, multiple transgenic mouse lines with cardiac-specific overexpression of MEF2A or MEF2C presented with cardiomyopathy at base line or were predisposed to more fulminant disease following pressure overload stimulation. The cardiomyopathic response associated with MEF2A and MEF2C was not further altered by activated calcineurin, suggesting that MEF2 functions independently of calcineurin in this response. In cultured cardiomyocytes, MEF2A, MEF2C, and MEF2-VP16 overexpression induced sarcomeric disorganization and focal elongation. Mechanistically, MEF2A and MEF2C each programmed similar profiles of altered gene expression in the heart that included extracellular matrix remodeling, ion handling, and metabolic genes. Indeed, adenoviral transfection of cultured cardiomyocytes with MEF2A or of myocytes from the hearts of MEF2A transgenic adult mice showed reduced transient outward K(+) currents, consistent with the alterations in gene expression observed in transgenic mice and partially suggesting a proximal mechanism underlying MEF2-dependent cardiomyopathy.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16469744     DOI: 10.1074/jbc.M510217200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  81 in total

Review 1.  Re-employment of developmental transcription factors in adult heart disease.

Authors:  Toru Oka; Jian Xu; Jeffery D Molkentin
Journal:  Semin Cell Dev Biol       Date:  2006-11-24       Impact factor: 7.727

Review 2.  Kruppel-like Factors (KLFs) in muscle biology.

Authors:  Saptarsi M Haldar; Osama A Ibrahim; Mukesh K Jain
Journal:  J Mol Cell Cardiol       Date:  2007-04-19       Impact factor: 5.000

3.  Regulation of lymphoid versus myeloid fate 'choice' by the transcription factor Mef2c.

Authors:  Sandra Stehling-Sun; Jessica Dade; Stephen L Nutt; Rodney P DeKoter; Fernando D Camargo
Journal:  Nat Immunol       Date:  2009-01-25       Impact factor: 25.606

4.  Network-based predictions of in vivo cardiac hypertrophy.

Authors:  Deborah U Frank; Matthew D Sutcliffe; Jeffrey J Saucerman
Journal:  J Mol Cell Cardiol       Date:  2018-07-17       Impact factor: 5.000

5.  Genome-wide analysis of histone marks identifying an epigenetic signature of promoters and enhancers underlying cardiac hypertrophy.

Authors:  Roberto Papait; Paola Cattaneo; Paolo Kunderfranco; Carolina Greco; Pierluigi Carullo; Alessandro Guffanti; Valentina Viganò; Giuliano Giuseppe Stirparo; Michael V G Latronico; Gerd Hasenfuss; Ju Chen; Gianluigi Condorelli
Journal:  Proc Natl Acad Sci U S A       Date:  2013-11-27       Impact factor: 11.205

6.  Steroid receptor coactivator-2 is a dual regulator of cardiac transcription factor function.

Authors:  Erin L Reineke; Ashley Benham; Benjamin Soibam; Erin Stashi; Heinrich Taegtmeyer; Mark L Entman; Robert J Schwartz; Bert W O'Malley
Journal:  J Biol Chem       Date:  2014-05-08       Impact factor: 5.157

7.  The positive transcription elongation factor b is an essential cofactor for the activation of transcription by myocyte enhancer factor 2.

Authors:  Masanori Nojima; Yehong Huang; Mudit Tyagi; Hung-Ying Kao; Koh Fujinaga
Journal:  J Mol Biol       Date:  2008-07-16       Impact factor: 5.469

8.  MicroRNA-1 negatively regulates expression of the hypertrophy-associated calmodulin and Mef2a genes.

Authors:  Sadakatsu Ikeda; Aibin He; Sek Won Kong; Jun Lu; Rafael Bejar; Natalya Bodyak; Kyu-Ho Lee; Qing Ma; Peter M Kang; Todd R Golub; William T Pu
Journal:  Mol Cell Biol       Date:  2009-02-02       Impact factor: 4.272

9.  Targeted deletion of the extracellular signal-regulated protein kinase 5 attenuates hypertrophic response and promotes pressure overload-induced apoptosis in the heart.

Authors:  Tomomi E Kimura; Jiawei Jin; Min Zi; Sukhpal Prehar; Wei Liu; Delvac Oceandy; Jun-ichi Abe; Ludwig Neyses; Arthur H Weston; Elizabeth J Cartwright; Xin Wang
Journal:  Circ Res       Date:  2010-01-14       Impact factor: 17.367

10.  MEF2C silencing attenuates load-induced left ventricular hypertrophy by modulating mTOR/S6K pathway in mice.

Authors:  Ana Helena M Pereira; Carolina F M Z Clemente; Alisson C Cardoso; Thais H Theizen; Silvana A Rocco; Carla C Judice; Maria Carolina Guido; Vinícius D B Pascoal; Iscia Lopes-Cendes; José Roberto M Souza; Kleber G Franchini
Journal:  PLoS One       Date:  2009-12-29       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.